Mutation Found Determines Nature of Host Response to MRSA Infection
|
By LabMedica International staff writers Posted on 22 Sep 2019 |

Image: A scanning electron micrograph (SEM) of a human neutrophil ingesting MRSA (Photo courtesy of the U.S. National Institute of Allergy and Infectious Diseases).
A recent paper described the genetic factors that determine why some individuals develop chronic methicillin-resistant Staphylococcus aureus (MRSA) infections while others develop infections that resolve relatively quickly.
The severity and duration of MRSA infection varies widely between individuals. Host factors predisposing to persistent MRSA infection are poorly understood, although genetic association studies are beginning to identify potentially influential variants.
Investigators at Duke University (Durham, NC, USA) searched for such host factors by analyzing two sets of patients who had been closely matched by age, sex, health conditions, and other risk factors for MRSA bloodstream infections. Sixty-eight patients were included in the study; half with a persistent MRSA infection and half who had been able to clear the infection from their bloodstream. Whole-exome sequencing was used to pinpoint genomic differences between the two sets of patients.
Results revealed that a mutation located in the DNA of the DNMT3A region of chromosome 2p was expressed in about 62% of the patients who cleared their MRSA infection, while it was expressed in only 9% in those who had persistent infections.
In a further series of experiments, the investigators demonstrated that DNMT3A variants could alter host response to infection through increased methylation of key regulatory genes, which resulted in reduced interleukin-10 production and in turn, allowed for a more protective immune response that cleared infection.
"The increasing prevalence of antibiotic resistant staph infections has created an urgent need to better understand who is most susceptible to these difficult-to-treat S. aureus infections and why," said senior author Dr. Vance Fowler, professor of medicine, molecular genetics, and microbiology at Duke University. "Our study identifies a particular DNMT3A mutation that contributes to an increased ability to resolve MRSA infections. The mechanism for this appears to be increased methylation of gene regulatory regions, and reduced levels of the anti-inflammatory cytokine IL-10."
The MRSA paper was published in the September 16, 2019, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.
Related Links:
Duke University
The severity and duration of MRSA infection varies widely between individuals. Host factors predisposing to persistent MRSA infection are poorly understood, although genetic association studies are beginning to identify potentially influential variants.
Investigators at Duke University (Durham, NC, USA) searched for such host factors by analyzing two sets of patients who had been closely matched by age, sex, health conditions, and other risk factors for MRSA bloodstream infections. Sixty-eight patients were included in the study; half with a persistent MRSA infection and half who had been able to clear the infection from their bloodstream. Whole-exome sequencing was used to pinpoint genomic differences between the two sets of patients.
Results revealed that a mutation located in the DNA of the DNMT3A region of chromosome 2p was expressed in about 62% of the patients who cleared their MRSA infection, while it was expressed in only 9% in those who had persistent infections.
In a further series of experiments, the investigators demonstrated that DNMT3A variants could alter host response to infection through increased methylation of key regulatory genes, which resulted in reduced interleukin-10 production and in turn, allowed for a more protective immune response that cleared infection.
"The increasing prevalence of antibiotic resistant staph infections has created an urgent need to better understand who is most susceptible to these difficult-to-treat S. aureus infections and why," said senior author Dr. Vance Fowler, professor of medicine, molecular genetics, and microbiology at Duke University. "Our study identifies a particular DNMT3A mutation that contributes to an increased ability to resolve MRSA infections. The mechanism for this appears to be increased methylation of gene regulatory regions, and reduced levels of the anti-inflammatory cytokine IL-10."
The MRSA paper was published in the September 16, 2019, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.
Related Links:
Duke University
Latest Microbiology News
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read moreMolecular Diagnostics
view channel
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more
Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Lung cancer remains the leading cause of cancer death worldwide, while heterogeneous tumor genetics continue to complicate treatment decisions. Although molecular testing is increasingly used to match... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








